AbbVie Inc

NYSE:ABBVUnited States

Today

Show headlines and story abstract

• Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating, from 5 hours ago by MT Newswires

  5 hours ago by MT Newswires
  Companies Mentioned: ABBV
  10:45 AM EST, 11/18/2024 (MT Newswires) -- AbbVie (ABBV) has an average outperform rating and a price target range of $165 to $240, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major b...

• Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products, from 7 hours ago by PR Newswire

  7 hours ago by PR Newswire
  Companies Mentioned: ABBV

  Seven new e-trainings, all 30 minutes or less, are available starting today through Allergan Medical Institute(R) (AMI) at AMIOnline.com

  Allergan Aesthetics, an AbbVie company, launched AMI Business Education, a new addition to the AMI Online learning platform available for free to all Allergan Aesthetics customers. This innovative offering empowers healthcare practitioners, their staff, and management with business education practices focused on Allergan Aesthetics products to enhance patient service and achieve operational excellence.

• Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products, from 7 hours ago by Dow Jones

  7 hours ago by Dow Jones
  Companies Mentioned: ABBV
  
  Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
  
  PR Newswire
  
  IRVINE, Calif., Nov. 18, 2024
  

• Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA, from 8 hours ago by MT Newswires

  8 hours ago by MT Newswires
  Companies Mentioned: ABBV, ALDX
  08:01 AM EST, 11/18/2024 (MT Newswires) -- Aldeyra Therapeutics (ALDX) said Monday that the US Food and Drug Administration has accepted its resubmitted new drug application for its topical ocular reproxalab, a treatment for dry eye disease. The com...

• DJ AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer, from 9 hours ago by Dow Jones

  9 hours ago by Dow Jones
  Companies Mentioned: ABBV
  
  By Colin Kellaher
  
  AbbVie has won European Commission approval of Elahere to treat adult patients with a type of ovarian cancer.
  
  AbbVie on Monday said the green light covers Elahere for treating adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.